On the other hand, the compounds and metabolites in SGR showed more stable binding to XOD and URAT1 than the target protein CNT2, and it suggest that SGR may be a potential candidate for drug design or functional food for the treatment of hyperuricemia, and based on the clarification of the conformational relationship of SGR, the enhancement of the inhibitory activity of XOD and URAT1 through structural modification may be an important future research direction. The gene discussed is SLC28A2; the disease is hyperuricemia.